Biomind Labs Stock Performance

BMNDF Stock  USD 0.11  0.00  0.00%   
Biomind Labs holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Biomind Labs' returns are expected to increase less than the market. However, during the bear market, the loss of holding Biomind Labs is expected to be smaller as well. Use Biomind Labs variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to analyze future returns on Biomind Labs.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Biomind Labs are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak fundamental indicators, Biomind Labs reported solid returns over the last few months and may actually be approaching a breakup point. ...more
  

Biomind Labs Relative Risk vs. Return Landscape

If you would invest  1.58  in Biomind Labs on November 10, 2025 and sell it today you would earn a total of  9.42  from holding Biomind Labs or generate 596.2% return on investment over 90 days. Biomind Labs is currently producing 7.464% returns and takes up 55.8383% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Biomind, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Biomind Labs is expected to generate 68.72 times more return on investment than the market. However, the company is 68.72 times more volatile than its market benchmark. It trades about 0.13 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of risk.

Biomind Labs Target Price Odds to finish over Current Price

The tendency of Biomind Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.11 90 days 0.11 
about 15.87
Based on a normal probability distribution, the odds of Biomind Labs to move above the current price in 90 days from now is about 15.87 (This Biomind Labs probability density function shows the probability of Biomind Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Biomind Labs has a beta of 0.57 suggesting as returns on the market go up, Biomind Labs average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Biomind Labs will be expected to be much smaller as well. In addition to that Biomind Labs has an alpha of 7.069, implying that it can generate a 7.07 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Biomind Labs Price Density   
       Price  

Predictive Modules for Biomind Labs

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biomind Labs. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biomind Labs' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.010.1155.61
Details
Intrinsic
Valuation
LowRealHigh
0.000.0855.58
Details

Biomind Labs Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Biomind Labs is not an exception. The market had few large corrections towards the Biomind Labs' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Biomind Labs, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Biomind Labs within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
7.07
β
Beta against Dow Jones0.57
σ
Overall volatility
0.05
Ir
Information ratio 0.13

Biomind Labs Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biomind Labs for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biomind Labs can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Biomind Labs is way too risky over 90 days horizon
Biomind Labs has some characteristics of a very speculative penny stock
Biomind Labs appears to be risky and price may revert if volatility continues
Biomind Labs has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (4.33 M) with profit before overhead, payroll, taxes, and interest of 0.
Biomind Labs has accumulated about 1.61 M in cash with (2.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Roughly 90.0% of the company shares are held by company insiders

Biomind Labs Fundamentals Growth

Biomind Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Biomind Labs, and Biomind Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biomind Pink Sheet performance.

About Biomind Labs Performance

By analyzing Biomind Labs' fundamental ratios, stakeholders can gain valuable insights into Biomind Labs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biomind Labs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biomind Labs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. Biomind Labs is traded on OTC Exchange in the United States.

Things to note about Biomind Labs performance evaluation

Checking the ongoing alerts about Biomind Labs for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Biomind Labs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Biomind Labs is way too risky over 90 days horizon
Biomind Labs has some characteristics of a very speculative penny stock
Biomind Labs appears to be risky and price may revert if volatility continues
Biomind Labs has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (4.33 M) with profit before overhead, payroll, taxes, and interest of 0.
Biomind Labs has accumulated about 1.61 M in cash with (2.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Roughly 90.0% of the company shares are held by company insiders
Evaluating Biomind Labs' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Biomind Labs' pink sheet performance include:
  • Analyzing Biomind Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biomind Labs' stock is overvalued or undervalued compared to its peers.
  • Examining Biomind Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Biomind Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biomind Labs' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Biomind Labs' pink sheet. These opinions can provide insight into Biomind Labs' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Biomind Labs' pink sheet performance is not an exact science, and many factors can impact Biomind Labs' pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Biomind Pink Sheet analysis

When running Biomind Labs' price analysis, check to measure Biomind Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomind Labs is operating at the current time. Most of Biomind Labs' value examination focuses on studying past and present price action to predict the probability of Biomind Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomind Labs' price. Additionally, you may evaluate how the addition of Biomind Labs to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Global Correlations
Find global opportunities by holding instruments from different markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital